Literature DB >> 4148917

Comparison of blockade at alpha-adrenoceptors by thymoxamine and phentolamine in peripheral arteries and veins of man.

J G Collier, C Nachev, B F Robinson.   

Abstract

1. The antagonism at alpha-adrenoceptors by thymoxamine and phentolamine of the response to noradrenaline was investigated in the limb veins and arteries of man.2. Brachial artery infusions of thymoxamine (40 mug/min) produced rises in resting arterial flow of up to 100%. When infused mixed with noradrenaline, thymoxamine (40 mug/min) attenuated the blood flow response to noradrenaline. Blockade was of a similar degree to that which occurred following a 10 min infusion of phentolamine (40 mug/min).3. Local intravenous infusion of thymoxamine (400-2,000 ng/min) mixed with noradrenaline attenuated the venoconstrictor response to noradrenaline. The degree of attenuation was similar to that seen after a 10 min infusion of phentolamine (500 ng/min). Blockade after thymoxamine did not last longer than 16 minutes. Neither thymoxamine nor phentolamine altered resting venous compliance.4. Local intravenous infusions of thymoxamine (500 ng/min) and phentolamine (500 ng/min) abolished the sympathetically mediated venoconstriction produced by overbreathing.5. Systemic injection of thymoxamine (0.1 mg/kg) did not block the reduction in forearm arterial flow produced by locally infused noradrenaline. In two out of three experiments, however, it produced some antagonism of noradrenaline induced venoconstriction. Systemic phentolamine (5 mg) blocked the effect of noradrenaline in the arterial bed, but antagonized its actions in the veins in only one out of three experiments.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4148917      PMCID: PMC1666089          DOI: 10.1111/j.1476-5381.1972.tb07266.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

1.  Competitive blockade of adrenergic alpha-receptors and histamine receptors by thymoxamine.

Authors:  A T Birmingham; J Szolcsányi
Journal:  J Pharm Pharmacol       Date:  1965-07       Impact factor: 3.765

2.  Relative affinities of some alpha-adrenoceptor blocking drugs in isolated human smooth muscle.

Authors:  I M Coupar; P Turner
Journal:  Br J Pharmacol       Date:  1970-09       Impact factor: 8.739

3.  A quantitative analysis of the antagonism of intravenous noradrenaline by thymoxamine or phentolamine on the blood pressure of the conscious cat.

Authors:  A T Birmingham; P I Akubue; J Szolcsányi
Journal:  J Pharm Pharmacol       Date:  1967-03       Impact factor: 3.765

4.  Phaeochromocytoma: a persistent diagnostic problem.

Authors:  P Richards; A R Adamson; G J Macdonald
Journal:  Lancet       Date:  1969-10-18       Impact factor: 79.321

5.  The distensibility characteristics of the capacitance vessels of the forearm in normal subjects.

Authors:  N Burki; A Guz
Journal:  Cardiovasc Res       Date:  1970-01       Impact factor: 10.787

6.  Antagonism of the response of human isolated arteries to noradrenaline.

Authors:  A T Birmingham; K Ernest; J F Newcombe
Journal:  Br J Pharmacol       Date:  1969-01       Impact factor: 8.739

7.  Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.

Authors:  J G Collier; N A Dawnay; C Nachev; B F Robinson
Journal:  Br J Pharmacol       Date:  1972-02       Impact factor: 8.739

  7 in total
  3 in total

Review 1.  Clinical pharmacology, physiology and pathophysiology of superficial veins--2.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

2.  Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.

Authors:  J G Collier; N A Dawnay; C Nachev; B F Robinson
Journal:  Br J Pharmacol       Date:  1972-02       Impact factor: 8.739

3.  Autonomic regulation of postprandial plasma somatostatin, gastrin, and insulin.

Authors:  M R Lucey; J A Wass; P Fairclough; J Webb; S Webb; S Medbak; L H Rees
Journal:  Gut       Date:  1985-07       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.